申请人:INTRA-CELLULAR THERAPIES, INC.
公开号:US20170283417A1
公开(公告)日:2017-10-05
The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HT
2A
receptor, serotonin transporter (SERT) and/or pathways involving dopamine D
2
receptor signaling systems.